- Home
- EYPT vs BFC Comparison
EYPT vs BFC Comparison
Compare EYPT & BFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EYPT | BFC |
|---|---|---|
| Founded | 1987 | 1894 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Major Banks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | EYPT | BFC |
|---|---|---|
| Price | $16.23 | $124.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $28.75 | ★ $142.00 |
| AVG Volume (30 Days) | ★ 1.2M | 56.9K |
| Earning Date | 11-05-2025 | 01-16-2026 |
| Dividend Yield | N/A | ★ 1.43% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.11 |
| Revenue | $42,339,000.00 | ★ $168,778,000.00 |
| Revenue This Year | N/A | $11.79 |
| Revenue Next Year | N/A | $32.03 |
| P/E Ratio | ★ N/A | $17.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $92.49 |
| 52 Week High | $19.11 | $139.71 |
Technical Indicators
Market Signals| Indicator | EYPT | BFC |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 43.09 |
| Support Level | $16.67 | $121.25 |
| Resistance Level | $18.20 | $125.34 |
| Average True Range (ATR) | 1.01 | 3.29 |
| MACD | -0.31 | -0.66 |
| Stochastic Oscillator | 2.85 | 22.22 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About BFC Bank First Corporation
Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.